Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Interview with Marina Lavrova
Read the short interview with Marina Lavrova, Quality director, Sphera - Pharm, Russia.
As you are going to speak about the changes that you have implemented recently in your company, can you reveal what were the reasons for those changes?
All companies go through the changes – planned or unplanned. We understand that the change management system requires agreed decisions and integration with quality risk management processes.
Implementation of computer systems for managing changes provides with benefits such as:
- Absolute transparency of change management process
- Reduction of the amount of time needed for change implementation
- Risk-oriented approach to change management
- Decreasing the amount of mistakes
- Exclusion of hard copies
...and – as conclusion – reduction of the overall costs for managing poor quality of a product.
Interview was made for the 1st annual of the Quality Assurance in Russian Pharma Manufacturing conference which took place on 27-28 of May 2015 in Moscow, Russia.
Find out more about the upcoming event:
Interested in this topic?
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Patient Engagement & Experience
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
Quality Requirements for Biotech Products from First-In-Human to Phase III
This unique three-day course will cover all the necessary information about quality requirements for biotech products, from non-clinical use to Phase III clinical trials. GMP, QbD, and QC principles are highly important for the safety and usability of emerging investigational medical products.